LOGO.png
Autolus Therapeutics to Present New Data at the 63rd ASH Annual Meeting & Exposition
November 04, 2021 09:01 ET | Autolus Therapeutics plc
- Demonstrates progress on the Company’s commercial manufacturing process and builds on positive obe-cel clinical data presented at EHA Conference Call and Webcast to be held Tuesday, December 14,...
LOGO.png
Autolus Therapeutics announces publication of obe-cel (AUTO1) Phase 1 ALLCAR19 data in adults with relapsed/ refractory B-ALL in Journal of Clinical Oncology
September 01, 2021 07:00 ET | Autolus Therapeutics plc
LONDON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
LOGO.png
Autolus Therapeutics Announces Promising Innovative Medicine (PIM) designation for obe-cel for the treatment of relapsed/refractory adult B-cell ALL
August 09, 2021 07:00 ET | Autolus Therapeutics plc
LONDON, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
LOGO.png
Autolus Therapeutics Announces Innovation Licensing and Access Pathway (ILAP) designation for obe-cel for the treatment of relapsed/refractory adult B-cell ALL
June 15, 2021 07:00 ET | Autolus Therapeutics plc
LONDON, June 15, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
LOGO.png
Autolus Therapeutics Presents New Data on obe-cel in r/r Indolent B Cell Lymphomas and gives an update of obe-cel in r/r Adult ALL at the European Hematology Association Virtual Congress
June 11, 2021 07:00 ET | Autolus Therapeutics plc
Obe-cel achieves 100% complete remission rate in a cohort of indolent B Cell Non-Hodgkin lymphoma patients with excellent CAR T engraftment, expansion, and persistence No ICANS or high grade...
LOGO.png
Autolus Therapeutics Announces an Additional Nature Publication for AUTO1
May 25, 2021 07:00 ET | Autolus Therapeutics plc
LONDON, May 25, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced a...
LOGO.png
Autolus Therapeutics to Present New Data on AUTO1 in r/r Indolent B Cell Lymphomas at the European Hematology Association Virtual Congress
May 12, 2021 10:00 ET | Autolus Therapeutics plc
AUTO1 achieves 100% complete remission rate in cohort of r/r Indolent Non- Hodgkin Lymphoma patients No high-grade cytokine release syndrome or neurotoxicity observed LONDON, May 12, 2021 ...
LOGO.png
Autolus Therapeutics Receives PRIME designation for AUTO1 for the treatment of adult ALL
April 01, 2021 08:45 ET | Autolus Therapeutics plc
LONDON, April 01, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
LOGO.png
Autolus Therapeutics presents compelling AUTO1 data from ALLCAR Phase 1 study in Adult Acute Lymphoblastic Leukemia (ALL) during the 62nd ASH Annual Meeting
December 05, 2020 15:01 ET | Autolus Therapeutics plc
Updated data from the ALLCAR study suggests AUTO1’s potential for transformational activity in adult patients with r/r ALL Conference call and webcast to be held Monday, December 7, 2020 at 4:00 pm...
LOGO.png
Autolus Therapeutics presents AUTO1 and AUTO3 data at the 2020 EHA25 Virtual Congress
June 12, 2020 02:30 ET | Autolus Therapeutics plc
Pivotal AUTO1 study in adult ALL patients enrolling -  AUTO1 continued favorable safety profile and high level of clinical activity, pivotal Phase 1b/2 AUTO1-AL1 program in adult ALL initiated and...